EBCC-14 News: Breast cancer patients can safely avoid extensive removal of lymph nodes if they respond well to primary systemic treatment Milan, Italy: Patients with breast cancer that has started to spread to the lymph nodes in the armpit can safely avoid extensive removal of the lymph nodes if their treatment is tailored
EBCC-14 News: Low-dose radiotherapy boost helps prevent local recurrence with better cosmetic outcomes in young breast cancer patients Milan, Italy: The vast majority of young patients given a low-dose boost of radiotherapy to the site where their breast cancer was removed in addition to whole breast radiotherapy, remained free of local recurrence after
EBCC-14 News AI tool predicts risk of side effects after surgery and radiotherapy in breast cancer patients Phase 3 clinical trial starts later this year Milan, Italy: A team of international researchers have developed an artificial intelligence (AI) tool that can predict which breast cancer patients may be at risk of side effects
EBCC-14 News: A combined PET-MRI scan could improve treatment for patients with early breast cancer Milan, Italy: Using a combined scanning technique on patients with early-stage breast cancer improved treatment in almost three out of ten cases in a trial presented at the 14th European Breast Cancer Conference today (Thursday). [1] Using the combined
EBCC-14 News: New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status Milan, Italy: New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug, pembrolizumab, to chemotherapy before and after surgery for breast cancer leads to better outcomes for patients regardless of their age
News from EBCC-14: Exercise helps patients with advanced breast cancer, especially if they are suffering with pain Milan, Italy: Taking part in an exercise programme reduced pain and fatigue, and improved quality of life for people with metastatic breast cancer, according to new results of a trial presented at the 14th European Breast
EBCC-14 News: Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer -- Final analysis of the ALEXANDRA/IMpassion030 phase 3 trial -- Milan, Italy: Patients with triple-negative breast cancer do not benefit from the addition of atezolizumab to their post-surgery chemotherapy treatment, according to the results of
EBCC-14 News: Genetic test identifies patients with triple negative breast cancer who are unlikely to respond to immunotherapies New results from the I-SPY2 phase 2 clinical trial Milan, Italy: Researchers have developed a genetic test that can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy drugs. This means
EBCC-14 NEWS: Exciting new research to look out for at EBCC-14 The Chairs of Europe’s most exciting international breast cancer conference are looking forward to a fascinating and varied three days in Milan. New results from cutting-edge clinical trials will, of course, be presented, but also innovative early/translational research, and issues around
EBCC-14 NEWS: Manifesto to address inequalities across Europe in access to innovation for patients with metastatic breast cancer All patients with metastatic breast cancer (mBC) should have equal access to the best treatments and outcomes wherever they live in Europe and regardless of prognosis, according to a manifesto to be agreed on
